These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

652 related articles for article (PubMed ID: 18042108)

  • 21. [Treatment of infections associated with Clostridium difficile].
    Szczesny A; Martirosian G
    Wiad Lek; 2003; 56(5-6):278-82. PubMed ID: 14526488
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Role of Clostridium difficile infection in the relapse of ulcerative colitis].
    Vilalta Castel E; Alcázar Montero MS; Navarro Gaspar C; Gimeno Aranguez M
    An Med Interna; 2002 Dec; 19(12):637-9. PubMed ID: 12593034
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Treatment strategies for recurrent and refractory Clostridium difficile-associated diarrhea.
    Stepan C; Surawicz CM
    Expert Rev Gastroenterol Hepatol; 2007 Dec; 1(2):295-305. PubMed ID: 19072422
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Meeting the challenge of recurrent Clostridium difficile infection.
    Johnson S
    J Hosp Med; 2012 Mar; 7 Suppl 3():S11-3. PubMed ID: 22407994
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Treatment of Clostridium difficile infection.
    Gerding DN; Muto CA; Owens RC
    Clin Infect Dis; 2008 Jan; 46 Suppl 1():S32-42. PubMed ID: 18177219
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The role of vancomycin and metronidazole for the treatment of Clostridium difficile-associated diarrhea.
    Tart SB
    J Pharm Pract; 2013 Oct; 26(5):488-90. PubMed ID: 23940121
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Occurrence and treatment of Clostridium difficile-associated diarrhea].
    Tvede M; Høiby N
    Ugeskr Laeger; 2006 Jun; 168(26-32):2579; author reply 2579-80. PubMed ID: 16824400
    [No Abstract]   [Full Text] [Related]  

  • 28. The case for vancomycin as the preferred drug for treatment of Clostridium difficile infection.
    Bartlett JG
    Clin Infect Dis; 2008 May; 46(10):1489-92. PubMed ID: 18419480
    [No Abstract]   [Full Text] [Related]  

  • 29. Clostridium difficile-associated diarrhea: risk factors, diagnostic methods, and treatment.
    Oldfield EC
    Rev Gastroenterol Disord; 2004; 4(4):186-95. PubMed ID: 15580153
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Increasing risk of relapse after treatment of Clostridium difficile colitis in Quebec, Canada.
    Pepin J; Alary ME; Valiquette L; Raiche E; Ruel J; Fulop K; Godin D; Bourassa C
    Clin Infect Dis; 2005 Jun; 40(11):1591-7. PubMed ID: 15889355
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Life-threatening infections with a new strain of Clostridium difficile].
    Krausz S; Bessems M; Boermeester MA; Kuijper EJ; Visser CE; Speelman P
    Ned Tijdschr Geneeskd; 2005 Sep; 149(38):2081-6. PubMed ID: 16201595
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Epidemiology, diagnosis and treatment of Clostridium difficile infection.
    Bassetti M; Villa G; Pecori D; Arzese A; Wilcox M
    Expert Rev Anti Infect Ther; 2012 Dec; 10(12):1405-23. PubMed ID: 23253319
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The challenges posed by reemerging Clostridium difficile infection.
    Blossom DB; McDonald LC
    Clin Infect Dis; 2007 Jul; 45(2):222-7. PubMed ID: 17578783
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Risk of Clostridium difficile infection after perioperative antibacterial prophylaxis before and during an outbreak of infection due to a hypervirulent strain.
    Carignan A; Allard C; Pépin J; Cossette B; Nault V; Valiquette L
    Clin Infect Dis; 2008 Jun; 46(12):1838-43. PubMed ID: 18462108
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Recurrent Clostridium difficile infection: a review of risk factors, treatments, and outcomes.
    Johnson S
    J Infect; 2009 Jun; 58(6):403-10. PubMed ID: 19394704
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Absence of pseudomembranes in Clostridium difficile-associated diarrhea in patients using immunosuppression agents.
    Nomura K; Fujimoto Y; Yamashita M; Morimoto Y; Ohshiro M; Sato K; Oyake T; Kowata S; Konishi H; Yoshikawa T; Ishida Y; Taniwaki M;
    Scand J Gastroenterol; 2009; 44(1):74-8. PubMed ID: 18781540
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [The diagnosis and treatment of Clostridium difficile enterocolitis].
    Chen C
    Zhonghua Yi Xue Za Zhi; 1991 Jun; 71(6):323-5, 24. PubMed ID: 1667496
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Current strategies for management of initial Clostridium difficile infection.
    Kelly CP
    J Hosp Med; 2012 Mar; 7 Suppl 3():S5-10. PubMed ID: 22407996
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Implications of the changing face of Clostridium difficile disease for health care practitioners.
    McFarland LV; Beneda HW; Clarridge JE; Raugi GJ
    Am J Infect Control; 2007 May; 35(4):237-53. PubMed ID: 17482995
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Relapsing infections with Clostridium difficile].
    Visser WE; Dingemans-Dumas AM; Bac DJ
    Ned Tijdschr Geneeskd; 2005 Oct; 149(43):2381-5. PubMed ID: 16277125
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 33.